Skip to content

Ketamine research published in 2025

Page 26 of 39: studies 501 to 520 of 780, newest first. Back to the ketamine overview

Studies

Esketamine and Ketamine use in the Adolescent Population for Treatment Resistent Depression: A Systematic Review

European Psychiatry April 1, 2025 G. Chen, Y. Li

IntroductionKetamine is widely recognized for its dissociative anesthetic properties, particularly in procedural sedation and severe pain management among children, adolescents, and young adults. Despite its noted applications, research investigating ketamine’s impact on mood and suicidality within this specific demographic remains limited. This retrospective review seeks to address this gap by...

Ketamine-Assisted Psychotherapy for Addiction: Mechanisms, Evidence, and Clinical Implications

April 1, 2025 Ryan D Ward

Substance use disorders (SUDs) are notoriously difficult to treat due to complex biopsychosocial underpinnings and high relapse rates. Recent evidence positions ketamine-assisted psychotherapy (KAP) as a promising intervention for treatment-resistant addiction. This review explores ketamine’s neurobiological mechanisms, its synergistic effect with psychotherapy, and clinical data supporting its...

Patient Experience with Intranasal Esketamine in Treatment-Resistant Depression: Insights from a Multicentric Italian Study (REAL-ESKperience)

Journal of Personalized Medicine April 1, 2025 Marco Di, M. Pepe, Giacomo D’andrea et al. 18 citations

Background. Treatment-resistant depression (TRD) is a prevalent, high-burden disorder. Esketamine nasal spray (ESK-NS) has been approved for, T.R.D.; and efficacy has been observed in both clinical trials and real-world studies. However, observations integrating patients’ perspective on this treatment are limited. This multicentric Italian study explored experiences with ESK-NS in TRD patients,...

Antidepressant effect of ketamine unrelated to dissociation: Results from an exploratory mediation analysis of the KET01-02 study

European Psychiatry April 1, 2025 Lars Arvastson, Evangelos Papanastasiou, Karin Schmid et al.

IntroductionCurrent ketamine-based therapies for treatment-resistant depression (TRD) can induce dissociative symptoms. A novel oral prolonged-release ketamine formulation (KET01) results in a lower and delayed peak concentration of ketamine, and a higher concentration of the metabolites norketamine and hydroxynorketamine than after intravenous administration. KET01 has limited dissociative...

Response to Ketamine Therapy in Anxious and Non-Anxious Major Depressive Disorder: A Meta-Analysis of Clinical Trials

European Psychiatry April 1, 2025 Ilídio Oliveira, A. L. Stephany, M. L. Geremias et al.

Introduction Anxious depression (AxD) as an independent diagnostic has been controversial, with many suggesting it as a transient state and others highlighting evidence of a worse outcome, severity, and increased suicide risk. The International Classification of Diseases (ICD-11) lists a related concept under 6A73, Mixed depressive and anxiety disorder. Previous literature on ketamine’s...

Detection of dissociative states in patients during the administration of Es-ketamine by monitoring with the Dissociative Experience Scale II (DES II) - Part I

European Psychiatry April 1, 2025 Cristina Serritella, Federica Ferraiuolo, Mark Piccirillo et al.

Introduction The effectiveness of Es-ketamine therapy in the treatment of psycho-pathological symptoms is the subject of growing interest in the scientific community. Through the use of validated psychometric instruments, this study aims to delineate more precisely the mechanisms of action and clinical potential of this therapy, contributing to the advancement of knowledge in psychiatry....

DOI: 10.1192/j.eurpsy.2025.414 (opens in new tab) Full text (opens in new tab) Dissociative disorders Dissociation chemistry Dissociative experiences scale Clinical global impression +2

Ketamine for Critically Ill Patients with Severe Acute Brain Injury: A Systematic Review with Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials.

Neurocritical care April 1, 2025 Trine Hjorslev Andreasen, Frederik Andreas Madsen, Marija Barbateskovic et al. 8 citations

Patients with severe acute brain injury have a high risk of a poor clinical outcome due to primary and secondary brain injury. Ketamine reportedly inhibits cortical spreading depolarization, an electrophysiological phenomenon that has been associated with secondary brain injury, making ketamine potentially attractive for patients with severe acute brain injury. The aim of this systematic review...

DOI: 10.1007/s12028-024-02075-2 (opens in new tab) Full text (opens in new tab) Ketamine Brain injuries Cortical spreading depression Intensive care units +3

Functional connectivity subtypes during a positive mood induction: Predicting clinical response in a randomized controlled trial of ketamine for treatment-resistant depression.

Journal of Psychopathology and Clinical Science April 1, 2025 Shabnam Hossein, Mary L Woody, Benjamin Panny et al. 3 citations

Ketamine has shown promise in rapidly improving symptoms of depression and most notably treatment-resistant depression (TRD). However, given the heterogeneity of TRD, biobehavioral markers of treatment response are necessary for the personalized prescription of intravenous ketamine. Heterogeneity in depression can be manifested in discrete patterns of functional connectivity (FC) in default...

DOI: 10.1037/abn0000951 (opens in new tab) Full text (opens in new tab) Depression treatment Brain connectivity Mood patterns Personalized medicine +1

The Use of Prophylactic Ketamine to Mitigate Postoperative Depressive Symptoms: A Systematic Review.

Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses April 1, 2025 Eleanor Yip, Desiree Fleck 1 citation

Depression is predicted to be the leading burden of disease worldwide by 2030 with a prevalence of 10% to 60% in the surgical population. Depressive symptoms in the perioperative population are associated with a myriad of grave complications, including higher morbidity and mortality. This systematic review aims to determine whether a single dose of intravenous ketamine can be used...

DOI: 10.1016/j.jopan.2024.05.026 (opens in new tab) Full text (opens in new tab) Surgical complications Systematic review Ketamine therapy Surgical depression +3

Hepatic adverse events associated with ketamine and esketamine: A population-based disproportionality analysis.

Journal of Affective Disorders April 1, 2025 Angela T H Kwan, Moiz Lakhani, Kayla M Teopiz et al. 11 citations

To determine whether there is disproportionate reporting of hepatobiliary disorders in the United States (US) FDA Adverse Event Reporting System (FAERS) for individuals prescribed ketamine or esketamine. We identified Medical Dictionary for Regulatory Activities (MedDRA) terms in the FAERS related to hepatobiliary disorders. Formulations of ketamine and esketamine were evaluated for the...

DOI: 10.1016/j.jad.2025.01.054 (opens in new tab) Full text (opens in new tab) Esketamine Drug-induced liver injury Hepatobiliary disorders Hepatotoxicity +9

Ketamine Treatment for Pediatric Refractory Obsessive: Five Open Label Cases.

Journal of Child and Adolescent Psychopharmacology April 1, 2025 Hannah S Ishimuro, Paula K Yanes-Lukin, Pablo H Goldberg et al. 6 citations

Importance: Selective serotonin reuptake inhibitors (SSRIs) and cognitive behavioral therapy are the first-line treatments for pediatric obsessive-compulsive disorder (OCD) populations. Due to their limited effectiveness, additional treatment options are needed. A new potential pharmacological medication treatment avenue for OCD is intravenous (IV) ketamine. Objective: This study aimed to...

DOI: 10.1089/cap.2024.0127 (opens in new tab) Full text (opens in new tab) Obsessive-compulsive disorder Ketamine therapy Adolescent mental health OCD Treatment +2

Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study.

European Neuropsychopharmacology April 1, 2025 Eduard Vieta, Nahida Ahmed, Celso Arango et al. 12 citations

Patients with treatment resistant depression (TRD) experience a greater negative impact on their functioning and productivity at home and in the workplace versus treatment-responsive patients. Here, we report the effects of esketamine nasal spray (NS) versus quetiapine extended release (XR) on functioning, work productivity and activity impairment. ESCAPE‑TRD (NCT04338321) was a 32-week...

Esketamine alleviated cardiomyocyte ferroptosis induced by oxygen-glucose deprivation/reoxygenation (OGD/R) via cyclic GMP-AMP synthase interactor.

Cytotechnology April 1, 2025 Jianjun Ouyang, Weiqiang Xiao, Di Wu et al. 8 citations

The use of tourniquets (TQ) during the total knee arthroplasty (TKA) induced ischemia-reperfusion (I/R) injury in the limb, resulting in the release of inflammatory cytokines and reactive oxygen species (ROS), therefore leading to myocardial damage. This study aimed to investigate the effects and molecular mechanism of Esketamine on myocardial injury (MI) caused by TQ-induced I/R injury. A...

DOI: 10.1007/s10616-025-00723-9 (opens in new tab) Full text (opens in new tab) Cardiomyocyte Ogd/r Sting #cardioprotection heart protection +6

Volumetric mesoscopic electrophysiology: a new imaging modality for the nonhuman primate.

Journal of Neurophysiology April 1, 2025 Tobias Teichert, László Papp, Ferenc Vincze et al. 1 citation

The primate brain is a densely interconnected organ whose function is best understood by recording from the entire structure in parallel, rather than parts of it in sequence. However, available methods either have limited temporal resolution (functional magnetic resonance imaging; fMRI), limited spatial resolution (macroscopic electroencephalography), or a limited field of view (microscopic...

Oral ketamine for rapid reduction of suicidal ideation in major depressive disorder: A midazolam-controlled randomized clinical trial.

Asian Journal of Psychiatry April 1, 2025 Asif Seraj, Mohammed Reyazuddin, R K Gaur et al. 11 citations

The simplest, most convenient, and least expensive way to treat depressed and suicidal patients with ketamine is to administer racemic ketamine by the oral route. We describe the first active-controlled randomized clinical trial of oral racemic ketamine for suicidal ideation associated with depression. Adult patients with major depressive disorder and expressed suicidal ideation were randomized...

Lithium attenuates ketamine-induced long-term neurotoxicity through DISC1-mediated GSK-3β/β-catenin and ERK/CREB pathways.

Toxicology Letters April 1, 2025 Ting-Ting Yang, Zi-Wen Guo, Fang Zhang et al. 2 citations

Ketamine, an antagonist of N-methyl-D-aspartate receptor, is extensively employed in pediatric anesthesia. Multiple studies have shown that repeated ketamine exposure induces neuroapoptosis, synaptic changes and cognitive deficits during neurodevelopment. Therefore, it is essential to elucidate the mechanisms of ketamine-induced neurotoxicity and develop therapies to mitigate its harmful...

DOI: 10.1016/j.toxlet.2025.02.012 (opens in new tab) Full text (opens in new tab) Disc1 Erk/creb pathway Gsk-3β/β-catenin pathway Neurotoxicity +5

Ketamine: An emerging agent in the management of neuropsychiatric disorders.

Asian Journal of Psychiatry April 1, 2025 Nathan Menke, Elizabeth Hoffman, Kelsey Gaylor et al. 4 citations

Ketamine's unique pharmacological profile, safety, modulation of multiple neurotransmitter systems, and ability to produce neuroplastic changes make it a subject of study with implications for a wide range of neuropsychiatric disorders beyond its traditional use as an anesthetic agent. This article aims to provide an overview of the pharmacology of ketamine and briefly discuss its emerging use...

DOI: 10.1016/j.ajp.2024.104351 (opens in new tab) Full text (opens in new tab) Cannabis Addiction treatment Substance dependence Mental health interventions +10

Increased sensitivity to psychomotor effects of ketamine enantiomers in the Wistar-Kyoto depression model.

Journal of Psychiatric Research April 1, 2025 Kristian Elersič, Anamarija Banjac, Marko Živin et al. 3 citations

Ketamine, a fast-acting antidepressant, is a racemic mixture, composed of equal amounts of R- and S-ketamine. Preclinical studies are comparing them to better understand their role in therapeutic and undesirable effects. An important research gap is that studies do not use long clinically relevant protocols to compare the desired and undesired effects of ketamine enantiomers in modeled and...

DOI: 10.1016/j.jpsychires.2025.02.061 (opens in new tab) Full text (opens in new tab) Depressive disorder Depression mood disorder Clinical depression Ketamine ketalar +10

Cannabidiol reverses myeloperoxidase hyperactivity in the prefrontal cortex and striatum, and reduces protein carbonyls in the hippocampus in a ketamine-induced schizophrenia rat model.

Schizophrenia Research April 1, 2025 Sofia de Almeida Queiroz, Linério Ribeiro de Novais Junior, Anita Beatriz Pacheco de Carvalho et al. 2 citations

Schizophrenia (SCZ) has limited treatment options, often with significant side effects. Cannabidiol (CBD), a non-euphoric phytocannabinoid, has shown potential as a novel therapeutic option in SCZ due to antipsychotic-like, anti-inflammatory, and antioxidant properties. We compared the therapeutic effects of CBD and risperidone (RISP) in a rat model of SCZ induced by sub-chronic ketamine (KET),...

Effect of esketamine on postoperative depression in women with breast cancer and preoperative depressive symptoms: The EASE randomized trial.

Journal of clinical anesthesia April 1, 2025 Qingfeng Wei, Mengmeng Li, Qiuling Du et al. 10 citations

To determine whether intraoperative low-dose esketamine ameliorates depression in women having breast cancer surgery. A prospective single-center double blind randomized placebo-controlled trial. Perioperative period, operating room, post anesthesia care unit and hospital ward. 108 women 18-65 years old who were scheduled for elective breast cancer surgery. All had preoperative depressive...